000 06437nam a2200397 i 4500
999 _c392163
_d392163
001 392163
003 ES-MaUEC
005 20230927174709.0
006 a|||| o|||| 00| 0
007 cr nn 008mamaa
008 130702s2013 xxua o |||| 0|eng d
020 _a9781627034845
024 7 _a10.1007/978-1-62703-484-5
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRM411
_b2013 EB
245 0 0 _aAntiviral Methods and Protocols
_cedited by Edwin Yunhao Gong
250 _a2nd edition 2013
264 1 _aTotowa, NJ
_bHumana Press
_c2013
300 _a1 recurso en línea (XIV, 452 páginas)
_b52 ilustraciones, 28 ilustraciones a color
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aMethods in Molecular Biology
_x1940-6029
_v1030
505 0 _aA Fluorescence-Based High Throughput Screening Assay to Identify HIV-1 Inhibitors -- A Homogeneous Time-Resolved Fluorescence Assay to Identify Inhibitors of HIV-1 Fusion -- Identification of HIV-1 Reverse Transcriptase Inhibitors Using a Scintillation Proximity Assay -- Biochemical Screening Assays to Identify HIV-1 Integrase Inhibitors -- HIV-1 Genotyping of the Protease-Reverse Transcriptase and Integrase Genes to Detect Mutations that Confer Anti-Retroviral Resistance -- In Vitro Kinetic Profiling of Hepatitis C Virus NS3 Protease Inhibitors by Progress Curve Analysis -- A Novel Hepatitis C Virus NS5B Polymerase Assay of De Novo Initiated RNA Synthesis Directed from a Heteropolymeric RNA Template -- Selecting and Characterizing Drug-Resistant Hepatitis C Virus Replicon -- A Cellular Replicon-Based Phenotyping Assay to Determine Susceptibility of Hepatitis C Virus Clinical Isolates to NS3/4A Protease Inhibitors -- Expression and Purification of Hepatitis C Virus Protease from Clinical Samples -- Surface Plasmon Resonance as a Tool to Select Potent Drug Candidates for Hepatitis C Virus NS5B Polymerase -- Amplification and Sequencing of the Hepatitis C Virus NS3/4A Protease and the NS5B Polymerase Regions for Genotypic Resistance Detection of Clinical Isolates of Subtypes 1a and 1b -- A Southern Blot Assay for Detection of Hepatitis B Virus Covalently Closed Circular DNA from Cell Cultures -- In Vitro Phenotyping of Recombinant Hepatitis B Virus Containing the Polymerase/Reverse Transcriptase Gene from Clinical Isolates -- Cell-Based Antiviral Assays for Screening and Profiling Inhibitors Against Dengue Virus -- A Duplex Real-Time RT-PCR Assay for Profiling Inhibitors of Four Dengue Serotypes -- High Throughput Screening Using Dengue Virus Reporter Genomes -- Fluorimetric and HPLC-Based Dengue Virus Protease Assays Using a FRET Substrate -- Expression and Purification of Dengue Virus NS5 Polymerase and Development of a High Throughput Enzymatic Assay for Screening Inhibitors of Dengue Polymerase -- Detection and Quantification of Flavivirus NS5 Methyl-transferase Activities -- Testing Antiviral Compounds in a Dengue Mouse Model -- Construction of Self-Replicating Subgenomic West Nile Virus Replicons for Screening Antiviral Compounds -- Methods for Screening and Profiling Inhibitors of Herpes Simplex Viruses -- In Vivo Evaluation of Antiviral Efficacy Against Genital Herpes Using Mouse and Guinea Pig Models -- A Fluorescence-Based High Throughput Screening Assay for Identifying Human Cytomegalovirus Inhibitors -- A Fluorescence-Based High Throughput Antiviral Compound Screening Assay Against Respiratory Syncytial Virus -- Screening and Evaluation of Anti-Respiratory Syncytial Virus Compounds in Cultured Cells -- Evaluation of Antiviral Efficacy Against Human Respiratory Syncytial Virus Using Cotton Rat and Mouse Models -- In Vivo Evaluation of Antiviral Compounds on Respiratory Syncytial Virus Using a Juvenile Vervet Monkey (Chlorocebus pygerythrus) Infection Model -- Methods to Determine Mechanism of Action of Anti-Influenza Inhibitors -- Methods for Evaluation of Antiviral Efficacy Against Influenza Virus Infections in Animal Models -- Development of a High Throughput Antiviral Assay for Screening Inhibitors of Chikungunya Virus and Generation of Drug-Resistant Mutations in Cultured Cells -- A Mouse Model of Chikungunya Virus with Utility in Antiviral Studies.
520 _aAlthough antiviral drugs have been successfully developed for some viral diseases, there remains a clear, unmet medical need to develop novel antiviral agents for the control and management of many viruses that currently have no or limited treatment options as well as a need to overcome the limitations associated with the existing antiviral drugs, such as adverse effects and emergence of drug-resistant mutations. The second edition of Antiviral Methods and Protocols features: All chapters are new and written by experts in the field, reflecting the major recent technical advances in antiviral research and discovery. This edition focuses on many important human viruses, such as human immunodeficiency virus type 1 (HIV-1), hepatitis viruses (hepatitis B and C viruses), herpes viruses, human respiratory syncytial virus (RSV), and influenza virus, while also featuring some important emerging viruses, such as dengue virus, West Nile virus, and chikungunya virus.  As a volume in the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.   Comprehensive and cutting-edge, Antiviral Methods and Protocols, Second Edition will serve as an excellent laboratory reference for pharmaceutical and academic biologists, medicinal chemists, and pharmacologists as well as for virologists in the field of antiviral research and drug discovery.
988 _aSpringer_Protocols_2013
650 7 _2embne
_9677566
_aAntivirales
776 0 8 _iPrinted edition:
_z9781627034838
776 0 8 _iPrinted edition:
_z9781627034852
776 0 8 _iPrinted edition:
_z9781493960354
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-62703-484-5
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b09/2023
_dz
_eb
_zSI